cannbis hyperemesis syndrome similar episodes seen but now liitke severe h/0 cannabis usein last 24 hrs tretment plan in usa
"cannabinoid hyperemesis syndrome" diagnosis treatment
cannabinoid hyperemesis syndrome no recent cannabis use differential diagnosis treatment 2025
PMID: 38456869
"The manifestations of cannabinoid hyperemesis syndrome are indistinguishable from those of CVS, with similar onset, duration, and frequency of episodes." - Sleisenger & Fordtran's Gastrointestinal and Liver Disease
| Rule Out | Tests |
|---|---|
| Bowel obstruction / perforation | Abdominal X-ray or CT abdomen/pelvis |
| Pancreatitis | Lipase, amylase |
| Cholecystitis / cholangitis | RUQ ultrasound, LFTs, bilirubin |
| Appendicitis | CT abdomen (if indicated) |
| Gastroparesis | History, consider gastric emptying scan later |
| DKA | BMP, glucose, urinalysis |
| Adrenal insufficiency | If recurrent, consider AM cortisol |
| Ectopic pregnancy (if female, reproductive age) | urine hCG |
| Nephrolithiasis | UA, CT |
| Intracranial pathology | Neuro exam; consider head CT if headache/focal signs |
| Pheochromocytoma | If hypertensive during episodes |
| Medication | Dose | Notes |
|---|---|---|
| Haloperidol | 0.05 mg/kg IV or 5 mg IV/IM (adults) | First-line for CHS in ED; dopamine D2 antagonist. Check QTc first - hold if QTc prolonged (males >460 ms, females >480 ms) |
| Lorazepam | 1-2 mg IV q4-6h | Adjunct; reduces anxiety/retching reflex |
| Droperidol | 1.25-2.5 mg IV/IM | Alternative to haloperidol; similar mechanism |
| Ondansetron | 4-8 mg IV | Often used but less effective in CHS than typical antiemetics |
| Metoclopramide | 10 mg IV | Second-line |
| Promethazine | 12.5-25 mg IV/IM | QTc caution; avoid in children |
"ED treatment of CHS includes the use of capsaicin cream as well as haloperidol or lorazepam." - Rosen's Emergency Medicine"The most effective treatment [in the ED] is cessation of marijuana use." - Rosen's Emergency Medicine (but this applies when cannabis is actively being used)
| Finding | Action |
|---|---|
| QTc prolonged | Avoid haloperidol/droperidol; use lorazepam + capsaicin |
| Urine THC negative (verified abstinence) | Pivot to CVS workup; start triptans |
| Positive imaging (obstruction, pancreatitis, etc.) | Treat underlying cause; do not diagnose CHS |
| Fails typical CHS treatment | Broaden differential; admit for monitoring |
| Female + reproductive age | Check hCG first |
h/0 of cannabis in last 24 hr si said
| Test | Purpose |
|---|---|
| BMP | Electrolytes, glucose, renal function |
| Lipase | Rule out pancreatitis |
| Urine hCG (females) | Rule out ectopic pregnancy |
| Urine drug screen | Confirm THC; rule out coingestants |
| UA | Rule out UTI, nephrolithiasis |
| Abdominal X-ray | Only if obstruction suspected |
| LFTs | If jaundice or RUQ pain present |
| Drug | Dose | Priority |
|---|---|---|
| Haloperidol | 5 mg IV/IM (adults); 0.05 mg/kg peds | First-line - most evidence in CHS |
| Droperidol | 1.25-2.5 mg IV/IM | Alternative first-line |
| Lorazepam | 1-2 mg IV q4-6h | Adjunct; reduces retching, anxiety |
| Metoclopramide | 10 mg IV q6h | Second-line if above unavailable |
| Ondansetron | 4-8 mg IV | Less effective in CHS than in other vomiting; use as add-on only |
Why haloperidol over ondansetron? CHS involves dysregulated dopaminergic/endocannabinoid pathways. D2 blockers (haloperidol, droperidol) are mechanistically superior to 5-HT3 blockers in this condition.
| Scenario | Disposition |
|---|---|
| Responds to ED treatment, tolerates PO, vitals stable | Discharge with close follow-up |
| Persistent vomiting, significant dehydration, electrolyte abnormalities | Admit |
| Diagnostic uncertainty (labs/imaging abnormal) | Admit for further workup |
is draminene 50 mg okay